Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease
Conclusions:
Our data suggest that, within our cohort of pediatric patients with CD, UST has long-term efficacy with no observed safety concerns. Dose adjustment may be helpful in achieving clinical remission.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Gastroenterology: Inflammatory Bowel Disease Source Type: research
More News: Crohn's Disease | Electronic Medical Records (EMR) | Gastroenterology | Inflammatory Bowel Disease | Nutrition | Pediatrics | Psoriasis | Stelara | Study